Navigation Links
REG Signs Agreement with Three Biodiesel Plants to Consolidate
Date:5/12/2009

Biodiesel industry leader to acquire 105 MGY of additional capacity in Iowa and Illinois to meet diesel market demand.

Ames, Iowa (Vocus) May 12, 2009 -- Renewable Energy Group® today announced it has entered into agreements to consolidate with three commercial-scale biodiesel plants. Western Iowa Energy, which operates a 30 MGY facility in Wall Lake, Iowa; Central Iowa Energy, LLC, which operates a 30 MGY facility Newton, Iowa; and Blackhawk Biofuels, LLC, which operates a 45 MGY facility in Danville, Ill., are involved in the transaction.

The facilities represent an additional 105 million gallons per year (MGY) of wholly-owned production capacity which would allow the combined entity to better position itself to meet anticipated demand from the petroleum industry's distillate fuel market.

Ownership of the operations of all four companies will be consolidated in a new holding company to be named Renewable Energy Group, Inc. The consolidated company will be owned by the current members of the three acquired companies and current Renewable Energy Group (REG®) investors, including Bunge North America, ED&F Man, Natural Gas Partners, NGP Energy Technology Partners, US Renewables Group (USRG) and West Central Cooperative. The transaction is subject to approvals by the shareholders of all four companies and to other conditions, including customary regulatory approvals.

REG's chairman and chief executive officer Jeff Stroburg cited demand by major petroleum distributors and oil refiners as a key factor in the decision to move forward with plant consolidation. "As the Renewable Fuels Standard (RFS) takes effect and our nation moves toward energy reform, the distillate market is demanding technical expertise, dependable supply, more efficient distribution and creative pricing options from major biodiesel partners," Stroburg said. Under the 2007 Energy Indepen
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test
2. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
3. SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program
4. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
5. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
6. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
7. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
8. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
9. New Generation Biofuels Signs Sales Contract with Catoctin Mountain Growers to Supply up to 370,000 gallons of Renewable Biofuel
10. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
11. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
REG Signs Agreement with Three Biodiesel Plants to Consolidate 
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... 11 VIA Pharmaceuticals,(Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today that,Lawrence ... Stewart, senior,vice president and chief financial officer, will ... Company 28th Annual Health Care Conference on,Tuesday, March ...
... FRANCISCO, Calif., March 11 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the discovery, development and commercialization of,novel small-molecule therapeutics, ... year ended December 31, 2007., Total revenue ... million, with a,net loss of $8.8 million. Total ...
... March 11 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... today announced that Dr. Leslie J. Browne,President and Chief ... and Company 28th Annual Health Care Conference.,The conference will ... Boston Marriott,Copley Place, Boston, Massachusetts., Dr. Browne,s presentation ...
Cached Biology Technology:Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 10Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 2Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 3
(Date:10/18/2014)... a sample of patients with undiagnosed, suspected genetic conditions, ... with a higher molecular diagnostic yield than traditional molecular ... JAMA . The study is being released to coincide ... , Exome sequencing, which sequences the protein­coding region of ... material present in a cell or organism), has been ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... N.H. New research from Plymouth State University and ... bleeding horseshoe crabs for biomedical purposes causes short-term changes ... crabs, population decline in parts of the east coast. ... the blue blood from almost half a million living ...
... (Feb. 19, 2014) -- There are more than a trillion ... our brains. Each of these neurons contains millions of proteins ... form the complex networks of the brain still remains as ... For the first time, a group of scientists has been ...
... its food plants and parasitoids, has been going on for ... (ACG), a protected area of approximately 1200 km2 in ... of moths and butterflies are estimated to live in ACG. ... also numbering thousands of species. However, most of those wasps ...
Cached Biology News:Biomedical bleeding affects horseshoe crab behavior 2Biomedical bleeding affects horseshoe crab behavior 3Watching how the brain works 2Almost 200 new species of parasitoid wasps named after local parataxonomists in Costa Rica 2
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: